高级检索
当前位置: 首页 > 详情页

Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]Department of Thoracic Surgery, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China
出处:
ISSN:

关键词: Chemoradiotherapy clinical complete response esophageal carcinoma

摘要:
Background Although a clinical complete response (cCR) after chemoradiotherapy (CRT) could lead to a better prognosis, the choice of a following strategy, such as surgical or non-surgical approach, remains controversial. Methods All articles relevant to a comparison of surgical and non-surgical treatment (including further definitive chemoradiotherapy or active surveillance) for esophageal carcinoma patients with a cCR after CRT were retrieved for meta-analysis. The final date for data retrieval was 30 June 2018. Results Four retrospective studies including 648 patients met the inclusion criteria: 620 with squamous cell carcinoma and 28 with adenocarcinoma. The CRT + surgery group had an advantage over the non-surgery group in regard to two-year disease-free survival (DFS); however, the two groups showed similar results in five-year DFS. The CRT + surgery group had an advantage over the non-surgery group in two-year overall survival (OS); nevertheless, the two groups showed similar results in five-year OS. Conclusions Based on the available evidence, the addition of surgery to thoracic locally advanced esophageal carcinoma patients with a cCR after neoadjuvant CRT provided no advantage to long-term survival. As an exception, the two-year DFS and OS could be improved. This research conclusion might be more suitable to patients with squamous cell carcinoma.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区:
出版当年[2018]版:
Q3 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版:
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [*1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Jiankanglu12, Shijiazhuang 050011, China.
通讯作者:
通讯机构: [1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]Department of Thoracic Surgery, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China [*1]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Jiankanglu12, Shijiazhuang 050011, China. [*2]Panjiayuan Nan Li 17th, Beijing 100021, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random [2]Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: An analysis of 124 patients [3]食管癌新辅助治疗后cCR患者的疗效评价 [4]启膈方对人食管癌细胞Eca109、TE13及Cx26表达的影响 [5]Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma [6]Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary? [7]Salvage Re-Irradiation Versus-Concurrent Chemoradiotherapy For Esophageal Squamous Cell Carcinoma Patients With Locally Relapse After Definitive Chemoradiotherapy [8]Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. [9]Analysis of failure patterns in patients with resectable esophageal squamous cell carcinoma receiving chemoradiotherapy [10]Comparison between late-course accelerated hyperfractionation radiotherapy and concurrent chemoradiotherapy in patients with esophageal carcinoma

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号